XTL BIOPHARMACEUTICALS news, videos and press releases
For more news please use our advanced search feature.
XTL BIOPHARMACEUTICALS - More news...
XTL BIOPHARMACEUTICALS - More news...
- XTL Biopharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Update
- XTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides Update
- XTL Biopharmaceuticals Reports First Quarter 2018 Financial Results & Provides Update
-
XTL Biopharmaceuticals Ltd. - XTLB Stock Chart Technical Analysis for 05-07-18
- XTL Biopharmaceuticals Ltd. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements
- XTL Biopharmaceuticals Reports Third Quarter 2017 Financial Results
- XTL Biopharmaceuticals Receives Notification From NASDAQ Regarding Continuing Listing Requirements
- XTL Biopharmaceuticals Reports First Half 2017 Financial Results & Provides Clinical and Operational Update
- XTL Biopharmaceuticals Unveils Additional Expanded hCDR1 Preclinical Data for the Treatment of Sjogren's Syndrome
- XTL Biopharmaceuticals Reports First Quarter 2017 Financial Results & Provides Clinical and Operational Update
- XTL Biopharmaceuticals Appoints Mr. Alex Rabinovich to its Board of Directors
- XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögren’s Syndrome
- XTL Biopharmaceuticals Reports 2016 Financial Results & Provides Clinical and Operational Update
- XTL Biopharmaceuticals Announces Closing of $2.8 Million Private Placement From Existing Investors
- XTL Biopharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Listing Requirement
- XTL Biopharmaceuticals Announces $2.5 Million Registered Direct Offering
- XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's Syndrome
- XTL Biopharmaceuticals Announces Ratio Change of its Depositary Receipt Program
- XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potental In the Treatment of Sjögren's Syndrome
- XTL Biopharmaceuticals to Present at Biotech Showcase
- XTL Biopharmaceuticals Reports Third Quarter 2016 Financial Results & Provides Clinical and Operational Update
- XTL Biopharmaceuticals Receives NASDAQ Notification Regarding Minimum Bid Requirements
- XTL Biopharmaceuticals Reports Second Quarter 2016 Financial Results & Provides Clinical and Operational Update
- XTL Biopharmaceuticals Announces the European Patent Office has Issued a Patent for its Lupus Drug hCDR1
- XTL Biopharmaceuticals to Present at Rodman & Renshaw Conference on September 12, 2016
- Promising Lupus Drug From XTL Biopharmaceuticals Could Be Life Changer In Projected $4 Billion Market
